World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
81
Citations
24790
World Ranking
3873
National Ranking
1921

Research.com Recognitions

  • 2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Elizabeth A. Grimm is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple interconnected fields focusing primarily on medicine, biochemistry, genetics, and molecular biology, with significant work in oncology, immunology, molecular biology, cellular and molecular neuroscience, and ophthalmology.

The scientist has contributed to a body of knowledge that includes diverse topics such as macrophage migration inhibitory factor, nuclear receptors and signaling, nanoplatforms for cancer theranostics, peptidase inhibition and analysis, nitric oxide and endothelin effects, ocular oncology and treatments, and CAR-T cell therapy research.

Frequent collaborators in their research include Jason Roszik, Dai Ogata, Yong Qin, Sühendan Ekmekçioğlu, and Matías A. Bustos.

The common venues where their work is published reflect their research focus and include Cancer Research, Cell Death and Disease, Blood, Cancers, and bioRxiv (Cold Spring Harbor Laboratory).

Notable recent publications include:

  • Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma (2022), published in Cell Death and Disease
  • iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation (2021), published in Frontiers in Oncology
  • A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) (2022), published in Blood
  • Multi-modal molecular programs regulate melanoma cell state (2022), published in Nature Communications
  • Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth (2022), published in Cancers

Elizabeth A. Grimm's research includes a focus on tumor biology, immune response modulation, signaling pathways involved in cancer progression, and innovative therapeutic approaches such as CAR-T cell therapy. Their work contributes important insights into melanoma and lymphoma as well as ocular oncology.

They have been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 2012.

Best Publications

  • Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

    Elizabeth A Grimm;A. Mazumder;H. Z. Zhang;S. A. Rosenberg

  • Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

    A. Gordon Robertson;Juliann Shih;Juliann Shih;Christina Yau;Ewan A. Gibb

  • Biological activity of recombinant human interleukin-2 produced in Escherichia coli

    Steven A. Rosenberg;Elizabeth A. Grimm;Michael Mcgrogan;Michael Doyle

  • Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor

    Michael T. Lotze;Elizabeth A. Grimm;Amitabha Mazumder;John L. Strausser

  • Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene

    Toshiyoshi Fujiwara;Elizabeth A. Grimm;Tapas Mukhopadhyay;Wei Wei Zhang

  • Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

    Elizabeth Ann Grimm;Keith M. Ramsey;Amitabha Mazumder;Debra J. Wilson

  • The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

    S. Farzana Hussain;David Yang;Dima Suki;Kenneth Aldape

  • DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.

    Laurie B. Owen-Schaub;Shin Yonehara;William L. Crump;Elizabeth A. Grimm

  • The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-24

    Eva G. Caudell;John B. Mumm;Nancy Poindexter;Suhendan Ekmekcioglu

  • Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

    Elizabeth A Grimm;R. J. Robb;Jack A Roth;L. M. Neckers

  • Uveal Melanoma: From Diagnosis to Treatment and the Science in Between

    Chandrani Chattopadhyay;Dae Won Kim;Dan S. Gombos;Junna Oba

  • Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

    Jahan S. Khalili;Shujuan Liu;Tania G. Rodríguez-Cruz;Mayra Whittington

  • Anvendelse av villtype p53-protein eller p53-kodende sekvens for fremstilling av et medikament for behandling av kreft.

    Zhang Wei-Wei;Roth Jack A;Fujiwara Toshiyoshi;Grimm Elizabeth A

  • Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency.

    Elizabeth Grimm;Benjamin Bonavida

  • A Retroviral Wild-type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis

    Toshiyoshi Fujiwara;Elizabeth A. Grimm;Tapas Mukhopadhyay;De Wei Cai

  • Therapeutic Effect of a Retroviral Wild-Type p53 Expression Vector in an Orthotopic Lung Cancer Model

    Toshiyoshi Fujiwara;De Wei Cai;Renee N. Georges;Tapas Mukhopadhyay

  • The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

    Mitsuru Tsudo;Carolyn K. Goldman;Kathleen F. Bongiovanni;Wing C. Chan

  • Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

    Julie A. Ellerhorst;Victoria R. Greene;Suhendan Ekmekcioglu;Carla L. Warneke

  • Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Differentiation Associated Gene-7 (mda-7/IL24): Biologic Outcome in Advanced Cancer Patients

    Alex W. Tong;John Nemunaitis;Dan Su;Yuan Zhang

  • Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma (vol 32, pg 204, 2017)

    A.G. Robertson;J.L. Shih;C. Yau;E.A. Gibb

Frequent Co-Authors

Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center
Jason Roszik
Jason Roszik The University of Texas MD Anderson Cancer Center
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center
Victor G. Prieto
Victor G. Prieto The University of Texas MD Anderson Cancer Center
Toshiyoshi Fujiwara
Toshiyoshi Fujiwara Okayama University
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Qingyi Wei
Qingyi Wei Duke University
Sunil Chada
Sunil Chada The University of Texas MD Anderson Cancer Center
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Rajagopal Ramesh
Rajagopal Ramesh University of Oklahoma Health Sciences Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Elizabeth A. Grimm

Trending Scientists

Recently Published Articles